AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01734499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
Study NCT01734499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-B Quality of Life
Description: The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
Study NCT01734499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACT-B Quality of Life
Description: The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
Study NCT05451758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
Study NCT05059561 — intervention group
Intervention type: RADIATION
Intervention: X-ray radiograghy
Description: Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
Study NCT00709072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS (Short Message Service) reminders
Description: SMS reminders sent every 2 weeks
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 5 mg tablet orally.
Study NCT05822973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 monocryl suture
Description: incision will be closed with absorbable suture
Study NCT05822973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 nylon suture
Description: incision will be closed with non-absorbable suture
Study NCT04226209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSSE
Description: Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
Study NCT04116905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
Study NCT04116905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
Study NCT02491463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3389245A_LD GROUP
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study NCT02491463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3389245A_HD GROUP
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study NCT02491463 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study NCT02491463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study NCT01098266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF plus Best Investigator's Choice (BIC)
Description: * NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Study NCT01098266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Best Investigator's Choice (BIC)
Description: * Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Study NCT01883544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1007
Study NCT01883544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALXN1007
Study NCT00891241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI 1195-101
Description: Single dose, bolus IV injection of LMI 1195
Study NCT03558230 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Constraint-Induced Movement Therapy
Description: The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
Study NCT03558230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Constraint-Induced Movement Therapy
Description: The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
Study NCT03829722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
Study NCT03829722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV once per week during radiation therapy (AUC=1).
Study NCT03829722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV once per week during radiation therapy (30mg/m\^2)
Study NCT03829722 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given 5 days/week for a total of 35 doses (70 gray total).
Study NCT01838915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics+Glutamine
Description: Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function.
Study NCT01838915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin, 20 g.
Study NCT03850028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 89Zr-atezolizumab PET scans
Description: The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151).
Study NCT04119128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
Study NCT04119128 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
Study NCT03842059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided detection
Description: We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
Study NCT03842059 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study NCT00851279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic irrigated ablation catheter
Description: Magnetic irrigated catheter to be used with the magnetic navigation system
Study NCT02644577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03558230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration applied to the wrist.
Study NCT03558230 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for vibration)
Description: No vibration applied to the wrist.
Study NCT02644577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Study NCT01966289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2
Study NCT01966289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
Study NCT01966289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110 is administered subcutaneously at 60 mg/m2
Study NCT03642496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
Study NCT03642496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Middle dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
Study NCT03642496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose ET019002- T Cells
Description: ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
Study NCT02881762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
Study NCT03887234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coracoclavicular ligament reconstruction
Description: Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
Study NCT03887234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coracoclavicular ligament reconstruction
Description: Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
Study NCT04278976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of CoBaTrICE
Description: The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process.
Study NCT03539601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Description: Applied twice a day (BID)
Study NCT03539601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone butyrate cream, 0.1%
Description: Applied BID
Study NCT03539601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus cream, 1%
Description: Applied BID
Study NCT03539601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crisaborole Vehicle
Description: Applied BID
Study NCT03671304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Versa
Description: Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 5 mg tablet orally.
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-statin Lipid-Modifying Therapy
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
Study NCT02584504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-statin Lipid-Modifying Therapy
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
Study NCT02584504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study NCT03874091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study NCT03874091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study NCT01117532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Four 90 minute group therapy classes of this behavioral intervention
Study NCT04271813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Sintilimab
Description: Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
Study NCT03145909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-176
Description: Intravenous infusion
Study NCT04407442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT04407442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC
Study NCT04407442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT02907489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: triple antibiotic paste with an anti-inflammatory drug
Description: Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
Study NCT01783379 — intervention group
Intervention type: DRUG
Intervention: micafungin
Description: 100mg/day infusion in 1 hour
Study NCT01151865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4.
Study NCT02170870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Study NCT01151865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
Study NCT02170870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Study NCT02170870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microlipid
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Study NCT02584504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study NCT00358202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime
Description: cefepime hydrochloride 1gm IM q24h
Study NCT02213666 — intervention group
Intervention type: DEVICE
Intervention: Intracardiac Imaging
Description: Imaging of the RAA and LAA with ICE and assessment of thrombus.
Study NCT03763448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrapatellar Fat Pad preservation
Description: In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
Study NCT02170870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Study NCT00358202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 1 gm IM q24h
Study NCT03483935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Description: Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.